Comparison of the efficacy and safety of programmed cell death protein 1 inhibitors combined with albumin-paclitaxel with or without platinum in the treatment of advanced metastasis or recurrent cervical cancer
Journal Title: Chinese Journal of Clinical Research - Year 2024, Vol 37, Issue 5
Abstract
<b>Objective</b> To compare the efficacy and safety of programmed cell death protein 1 (PD-1) inhibitor + albumin paclitaxel and platinum + PD-1 inhibitor + albumin-paclitaxel in the treatment of advanced metastasis or recurrent cervical cancer. <b>Methods</b> The clinical data of patients who had advanced metastatic or recurrent cervical cancer were treated with PD-1 inhibitor + albumin paclitaxel + platinum (group A) or anti-PD-1 + albumin-bound paclitaxel (group B) in more than second-line therapy in the Affiliated Cancer Hospital of Nanjing Medical University from September 2018 to December 2022 were retrospectively analyzed. The objective response rate (ORR), progression-free survival (PFS) and the incidence of adverse reactions between the two groups were compared. <b>Results</b> A total of 54 patients were collected, 37 in group A and 17 in group B. The median age was 53 years old, and the average follow-up time was 10 months. Among the patients, 45 cases were squamous cell carcinoma, 6 cases were adenocarcinoma, 1 case was adenosquamous carcinoma, and 2 cases were neuroendocrine small cell carcinoma. There was no statistically significant difference in the ORR between group A and group B (35.30% vs 35.14%, P>0.05). There was no statistical significant difference in PFS between group A and group B (11.7 month vs 7.3 month, P>0.05). The differences in the incidence of adverse reactions, the incidence of adverse reactions with grade 3 and above, and the incidence of immune-related adverse reactions between the two groups were not statistically significant (P>0.05). <b>Conclusion</b> The PD-1 inhibitor + albumin paclitaxel + platinum regimen does not increase the efficacy compared with the PD-1 inhibitor + albumin paclitaxel regimen in more than second-line therapy of advanced metastatic and recurrent cervical cancer.
Authors and Affiliations
SHEN Jing*, XU Jingjing, LYU Mengmeng, WU Dongchen, WANG Jinhua
Keywords
Related Articles
- EP ID EP736341
- DOI 10.13429/j.cnki.cjcr.2024.05.038
- Views 18
- Downloads 0
Visual analysis of domestic and international hotspots of nutritional research in children with tumors
<b>Objective</b> To analyze the literatures related to the nutrition of children with tumors at home and abroad, and sort out the current status, hotspots and frontiers of the research in this field, so as to provide a...
Comparison of six frailty assessment tools for predicting short-term adverse outcomes in elderly colorectal cancer patients after surgery
<b>Objective</b> Preoperative frailty in elderly patients with colorectal cancer was evaluated using six frailty assessment tools, frailty phenotype (FP), frailty scale (FRAIL), clinical frailty scale (CFS), Tilburg frai...
Surgical treatment of secondary hyperparathyroidism in patients with chronic renal failure
Secondary hyperparathyroidism (SHPT), as a common complication of chronic renal failure, has always been a focus of clinical research on the treatment of parathyroidism. The pathogenesis of SHPT is due to the abnormal se...
Development of navigation assisted minimally invasive spine surgery
In recent years, minimally invasive spine surgery (MISS) has gradually become a feasible, highly effective and popular method for the treatment of various spinal diseases. Compared to traditional open surgery, MISS has m...
Effect of extended InterTAN intramedullary nail internal fixation on elderly femoral intertrochanteric fractures
Objective To explore the effect of extended InterTAN intramedullary nail internal fixation in the treatment of elderly femoral intertrochanteric fractures and its influence on hip function and incidence rates of complica...